Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

Novartis UK launches first health-tech investor partnership to address cardiovascular care

Novartis UK launches first health-tech investor partnership to address cardiovascular care

Novartis also hopes to help prevent future heart attacks or strokes through home-based digital solutions. ... Additionally, successful applicants will have access to the Novartis Biome UK system, alongside.

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

Novartis announces positive phase 3 trial results for advanced oesophageal cancer Through a collaboration and licence agreement with BeiGene, Novartis has the rights to develop, manufacture and commercialise tislelizumab in North America, Europe and Japan. ... combinations across additional tumour types that may benefit from an

HTA guidance from NICE, the SMC and the AWMSG

Published: 04 May 2022. 1 Jul 2022. The National Institute for Health and Care Excellence (NICE) has issued a final draft recommendation for Novartis Pharmaceuticals UK’s Scemblix (asciminib) for patients

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia The National Institute for Health and Care Excellence (NICE) has issued a final draft recommendation for Novartis Pharmaceuticals UK’s Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukaemia ... Heather Moses,

Novartis and Precision BioSciences announce in vivo gene editing collaboration

Novartis and Precision BioSciences announce in vivo gene editing collaboration Novartis and Precision BioSciences (Precision) have announced an in vivo gene editing research and development collaboration to develop potentially curative treatments for disorders including sickle cell disease (SCD) and beta thalassaemia.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....